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IκB kinase 2 (IKK2) is well known for its pivotal role as a mediator of the canonical NF-κB
pathway, which has important functions in inflammation and immunity, but also in cancer.
Here we identify a novel and critical function of IKK2 and its co-factor NEMO in the activation
of oncogenic c-Jun N-terminal kinase (JNK) signaling, induced by the latent membrane
protein 1 (LMP1) of Epstein-Barr virus (EBV). Independent of its kinase activity, the TGFβ-
activated kinase 1 (TAK1) mediates LMP1 signaling complex formation, NEMO ubiquitination
and subsequent IKK2 activation. The tumor progression locus 2 (TPL2) kinase is induced by
LMP1 via IKK2 and transmits JNK activation signals downstream of IKK2. The IKK2-TPL2-JNK
axis is specific for LMP1 and differs from TNFα, Interleukin−1 and CD40 signaling. This
pathway mediates essential LMP1 survival signals in EBV-transformed human B cells and
post-transplant lymphoma, and thus qualifies as a target for treatment of EBV-induced
cancer.
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The latent membrane protein 1 (LMP1) serves as the proto-type of a herpesviral oncoprotein. It is expressed byEpstein-Barr virus (EBV), a γ-herpesvirus causing lym-
phoproliferative and malignant diseases in humans1,2. LMP1
critically contributes to the pathogenesis of B-cell-derived infec-
tious mononucleosis, Hodgkin’s lymphoma and fatal post-
transplant lymphoproliferative disease (PTLD), as well as play-
ing an important role in the development of EBV-associated
nasopharyngeal carcinoma2,3. B cell transformation by the virus
depends on LMP1, which mimics stimulatory signals usually
provided by the CD40 receptor4–7. LMP1 causes oncogenic cell
transformation in rodent fibroblasts and LMP1-transgenic mice
develop hyperproliferation and inflammation, or malignancies,
dependent on the tissue and cell type, in which the viral oncogene
is expressed8–12.
Functioning as constitutively active receptor, LMP1 deregulates
cellular pathways involved in proliferation and survival signaling
including NF-κB, PI3-kinase, and the MAP kinases c-Jun N-
terminal kinase (JNK), ERK and p381. LMP1 consists of a short
N-terminal region linked to six transmembrane helices, which
mediate LMP1 activation by spontaneous autoaggregation. The
C-terminal cytoplasmic domain (amino acids 187–386) harbors
the C-terminal activator regions one (CTAR1, aa 194–232) and
two (CTAR2, aa 351–386), which are both required for viral cell
transformation1. Similar to TNF receptors (TNFR) or members of
the Interleukin-1/Toll-like receptor (IL-1/TLR) family, LMP1
recruits TNFR-associated factors (TRAFs). TRAF1, 2, and 3
directly bind to CTAR1, the region that induces noncanonical
NF-κB, PI3-kinase, and MAPK signaling1,13. CTAR2 recruits
TRAF6 and the TNFR-associated death domain protein
(TRADD) to activate canonical NF-κB and JNK as the primary
readouts of this subdomain14–19. Both CTAR2-induced pathways
are required for proliferation and survival of EBV-transformed B
cells20,21. TRAF6 is essential for CTAR2 function17–19. It pos-
sesses lysine 63-linked ubiquitin ligase activity. Accordingly, K63-
linked, but also linear ubiquitin chains, are important for LMP1
downstream signaling22,23. The Ste20 germinal center kinase
TNIK, the transforming growth factor-β-activated kinase 1
(TAK1), and the TAK1 binding proteins (TAB) 1–3 are involved
in JNK and canonical NF-κB signaling downstream of
TRAF619,24–26.
The transcription factor NF-κB is a key regulator of inflam-
mation and immunity, which is often found deregulated in
lymphoid malignancies and other cancer types27–29. The cano-
nical NF-κB pathway converges with the noncanonical pathway
at the IκB kinase (IKK) complex, which is also the case in
LMP1 signal transduction1,30. The IKK complex comprises two
catalytic components, IKK1 (also named IKKα) and IKK2
(IKKβ). The regulatory factor NEMO (IKKγ) is essential for the
canonical NF-κB pathway and acts by binding and activating
IKK2 dimers31. IKK2 requires phosphorylation within its acti-
vation loop to be active. TAK1 can phosphorylate IKK2 at serine
177, which is a priming event for IKK2 autophosphorylation at
serine 181, resulting in IKK2 activation in IL-1 signaling32,33.
IKK2 in turn phosphorylates IκBα, whose consequent degrada-
tion leads to the liberation and nuclear translocation of canonical
NF-κB dimers containing the transcription factor p65 NF-κB28,34.
IKK2 is essential for NF-κB induction by LMP1-CTAR2 in most
situations18,26,35. Functions of IKK2 in LMP1-mediated or cel-
lular JNK signaling have not been reported.
The serine/threonine kinase TPL2 (tumor progression locus 2),
also known as Cot or MAP3K8, plays an important role in
inflammation, immunity and tumorigenesis36,37. TPL2 primarily
activates the ERK pathway in response to various stimuli
including cytokines, growth factors or stress37–39. Also CD40
relies on TPL2 to activate ERK40. In some cell types, TPL2
contributes to the optimal activation of p38 MAPK and JNK,
specifically in response to genotoxic stress or inflammatory sti-
muli such as TNFα or IL-1β41–44. TPL2 crosstalks to the NF-κB
pathway37. In its inactive state, TPL2 protein is stabilized and
inhibited by complex formation with the IκB protein p105, the
precursor of p50 NF-κB. Upon agonist stimulation, p105 is
phosphorylated by IKK2, which causes p105 degradation and
subsequent TPL2 activation and destabilization37. Activation-
induced p105 degradation releases Rel subunits complexed with
p10530. Further, a non-essential role of TPL2 in NF-κB signaling
by LMP1 has been suggested26,45.
Precise knowledge of the LMP1 signaling network is a pre-
requisite for its exploitation as a target for the treatment of EBV-
associated cancer. However, the molecular mechanisms of
CTAR2 signaling in particular are not fully understood. In
addition to the architecture of the CTAR2 complex itself, the
contributions of signaling mediators such as IKKs, TAK1 or TPL2
to CTAR2 function are insufficiently defined or
controversial19,26,45–47. Here we investigate the functions of IKK2
in CTAR2 signaling and discover an unexpected and critical role
of this IKK isoform in JNK activation by LMP1. TPL2 transmits
JNK activation signals downstream of IKK2, which is a new role
for this MAP3K in cellular signaling. The IKK2-TPL2-JNK
pathway mediates survival and proliferation of EBV-transformed
B cells and of LMP1-expressing primary tumor cells established
from PTLD biopsies. Our results extend the biological functions
of IKK2 and TPL2 to a critical role in JNK activation.
Results
Genetic analysis of IKK2 function in LMP1-CTAR2 signaling.
To investigate the role of IKK2 in the LMP1 signaling network we
transduced wildtype and IKK2−/− mouse embryonic fibroblasts
(MEFs) with NGFR-LMP1, a fusion protein of the extracellular
and transmembrane domains of p75 NGF-receptor and the sig-
naling domain of LMP1 (Fig. 1a). This chimera can be activated
by crosslinking with NGFR-directed antibodies at the cell surface,
allowing the time-resolved analysis of direct LMP1 signaling
events17,48. NGFR-LMP1(Y384G) harboring an inactivated
CTAR2 was included to define the pathways that are initiated at
this subdomain. Equivalent surface expression of the NGFR-
LMP1 chimeras was confirmed by flow cytometry (Fig. 1b).
NGFR-LMP1 crosslinking triggered the fast response of JNK and
canonical NF-κB (Fig. 1c). The Y384G mutant failed to induce
both pathways, demonstrating that JNK and canonical NF-κB are
activated at CTAR2 (Fig. 1c). However, NGFR-LMP1(Y384G)
was still able to induce the depletion of TRAF3 from NP-40-
soluble cell fractions, excluding the possibility that NGFR-LMP1
(Y384G) was simply dysfunctional (Fig. 1d). TRAF3 extinction is
an early step in the activation of the noncanonical NF-κB path-
way, which is triggered at CTAR11,30. Taken together, MEFs
expressing NGFR-LMP1 constitute a suitable system to study
immediate CTAR2 signaling events leading to NF-κB and JNK
activation. First, we analysed the role of IKK2 in the canonical
NF-κB pathway. IKK2 was essential for NGFR-LMP1 to induce
IκBα degradation (Fig. 1e) and the translocation of p65 NF-κB
into the nucleus (Fig. 1f). The remaining IKK1 was apparently
unable to rescue the knockout of IKK2 in the canonical pathway.
These results further confirmed functionality of the experimental
system and demonstrated that IKK2 is in fact indispensable for
canonical NF-κB activation by CTAR2 in these cells.
IKK2 is critical for JNK activation by LMP1. In examining the
activity of the JNK pathway in IKK2−/− cells we made a sur-
prising observation. JNK activation by NGFR-LMP1 was almost
completely blocked by the absence of IKK2, suggesting an
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important and so far overlooked function of this IKK isoform in
the LMP1 signaling pathway to JNK (Fig. 2a). Also the siRNA-
mediated knockdown of IKK2 was sufficent to inhibit
LMP1 signaling to JNK (Supplementary Fig. 1a). To further
demonstrate that IKK activity is required for this pathway, the
impact of IKK inhibitor VIII (ACHP) on JNK activation by LMP1
was tested. Indeed, ACHP reproduced the effects of IKK2 defi-
ciency by blocking NGFR-LMP1-induced JNK1 activity (Fig. 2b).
In summary, three different approaches of interference with IKK2
function verified the critical role of this IKK isoform in the JNK
pathway.
LMP1 combines molecular features of TNFR and IL-1/TLR
signaling, but it also uses unique mechanisms to exploit cellular
signaling components, such as TRADD1,49. We tested, if the latter is
also true for IKK2. In contrast to LMP1, TNFα was able to induce
the JNK pathway in MEFs lacking IKK2, whereas both receptors
relied on IKK2 to activate canonical NF-κB (Fig. 2c, compare to
Fig. 1e, 2a). IL-1 activated both JNK and NF-κB in the absence of
IKK2, although the response of the NF-κB pathway to IL-1 was
slightly attenuated in IKK2−/− cells (Fig. 2d). This observation is in
line with published data demonstrating that IKK1 can substitute for
IKK2 in NF-κB signaling mediated by IL-150. We concluded that
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Fig. 1 Analysis of time-resolved signal transduction events induced by the CTAR2 domain of LMP1 through IKK2. a Schematic representation of the
NGFR-LMP1 (NL) fusion constructs used in this study, compared to wildtype LMP1 (right). Y384G mutation results in a dysfunctional CTAR2 domain.
Activity of NGFR-LMP1 can be triggered by NGFR-directed antibody crosslinking. bWildtype and IKK2-deficient mouse embryonic fibroblasts (MEFs) were
retrovirally transduced with NGFR-LMP1 or, in the case of wildtype MEFs, also with NGFR-LMP1(Y384G). Equivalent surface expression of the chimeras
was confirmed by flow cytometry. MFI mean fluorescent intensity. c Activation of canonical NF-κB and JNK is instantly triggered at CTAR2. NGFR-LMP1
constructs were activated with NGFR antibody and a crosslinking secondary antibody for the indicated times (X-link). IκBα levels and JNK phosphorylation
were detected by immunoblotting. Apparent molecular weights are given in kDa. d CTAR1-induced TRAF3 depletion remains unaffected by CTAR2
inactivation. Immunoblot analysis of detergent-soluble TRAF3 protein levels after crosslinking. e Canonical NF-κB activation by LMP1 in MEF cells depends
on IKK2. f LMP1-induced p65 NF-κB translocation into the nucleus requires IKK2. Cytoplasmic and nuclear p65 NF-κB levels were analysed after antibody
crosslinking. b–f The data are representative of at least two independent experiments. c–f For immunoblot quantification and statistics see Supplementary
Table 3.
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Fig. 2 Essential functions of IKK2 and NEMO in JNK activation by LMP1. a LMP1 fails to induce JNK after the knockout of IKK2 in MEFs. LMP1 activity
was induced by antibody crosslinking and JNK activation was monitored by immunoblotting. b Pharmacological inhibition of IKK activity interferes with JNK
activation by LMP1. NGFR-LMP1 was induced in the presence of solvent (DMSO) or 5 μM of the IKK inhibitor VIII (ACHP). c, d IKK2 has a unique role in
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a–f The data are representative of at least two independent experiments. For immunoblot quantification and statistics see Supplementary Table 3.
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IKK2 has an important role in LMP1 signaling to JNK, which
significantly differs from its functions in TNFα and IL-1
signaling.
LMP1 activates JNK through NEMO, while IKK1 is dis-
pensable. We explored the role of the remaining IKK complex
components IKK1 and NEMO in JNK activation by LMP1. The
siRNA-mediated knockdown of IKK1, an essential component of
the noncanonical NF-κB pathway, left JNK activation by NGFR-
LMP1 unaffected, whereas the downmodulation of IKK2 strongly
interfered with JNK signaling (Supplementary Fig. 1a). Next, we
targeted IKK1 with the help of CRISPR/Cas9 in wildtype and
IKK2−/− MEFs, both expressing NGFR-LMP1. The knockout of
IKK1 had no critical effect on JNK activation (Fig. 2e and Sup-
plementary Fig. 1b). Conversely, the knockout of NEMO blocked
JNK activation induced by NGFR-LMP1 (Fig. 2f). Taken together,
LMP1 uses the canonical IKK complex components NEMO and
IKK2 to induce JNK.
Differential functions of TAK1 in JNK and NF-κB signaling.
To gain deeper insight into the molecular mechanism that
underlies the observed functions of IKK2 in LMP1 signaling, we
investigated the role of the IKK2 kinase TAK1 in this process.
First, we tested if inhibition of TAK1 kinase activity by the
irreversible TAK1-specific inhibitor (5Z)−7-oxozeaenol (TAK1-
IH) had an effect on JNK or canonical NF-κB activation by
LMP1. Although our data have shown that IKK2 is essential for
both pathways, only JNK activation was down-regulated by TAK1
inhibition (Fig. 3a). This result raised the possibility that TAK1
has no function in IKK2 activation by LMP1. To address this
point, we targeted TAK1 in HEK293 cells and tested the effects of
TAK1 deficiency versus inhibition of its enzymatic activity on
IKK2 and JNK1 activation in parallel kinase activity assays
(Fig. 3b, c, respectively). Surprisingly, the knockout of TAK1
blocked both IKK2 and JNK1 activation, whereas inhibition of
TAK1 kinase activity selectively interfered with JNK1 activation.
Moreover, only the complete absence of TAK1 protein was suf-
ficient to abrogate LMP1-induced phosphorylation of IKK2 at
serines 177 and 181, the critical step in IKK2 activation (Fig. 3b).
Supporting IKK2 autophosphorylation rather than TAK1-
mediated phosphorylation as the mechanism of IKK2 activa-
tion, the IKK kinase inhibitor ACHP blocked serine 177/181
phosphorylation, whereas the TAK1 inhibitor had no effect
(Fig. 3d). These data indicated that (i) the TAK1 protein, but not
its kinase activity, is essential for IKK2 activation and conse-
quently IKK2 downstream signaling to JNK and NF-κB, (ii)
TAK1 does not function as an IKK2 kinase in LMP1 signaling,
and (iii) TAK1 kinase activity has a role in JNK activation parallel
to IKK2. The data clearly demonstrated, however, that the TAK1-
IKK2 axis is critical for JNK activation by LMP1.
Next we asked about the molecular role of the TAK1 protein in
IKK2 activation by LMP1. We have shown above that NEMO is a
component of the LMP1 pathway to JNK. Ubiquitination of
NEMO is an important step in IKK2 activation28. Indeed, LMP1
induced the K63-linked ubiquitination of NEMO, which was
inhibited in the absence of TAK1 (Fig. 3e). In contrast,
pharmacological TAK1 kinase inhibition had little effect on
NEMO ubiquitination at an inhibitor concentration that was
sufficient to block JNK activation by LMP1 (Fig. 3e, compare to
Fig. 3c). This result further strengthens the conclusion that TAK1
has an important function in activation of the canonical IKK
complex, which is independent of TAK1 kinase activity.
LMP1 forms a signaling complex incorporating IKK2 and both
proteins can be precipitated together from lymphoblastoid cells
(LCLs)49. A possible function of TAK1 in the IKK2 pathway may
be to mediate complex formation, which results in IKK2
activation. HA-LMP1 interacted with Flag-IKK2 immunopreci-
pitated from transiently transfected HEK293 cells (Fig. 3f). Co-
precipitation of both proteins was also possible vice versa
(Supplementary Fig. 2a). Interaction of both proteins was lost
in the absence of TAK1 in TAK1crKO cells (Fig. 3f and
Supplementary Fig. 2a). Furthermore, NEMO has a function in
signaling complex formation, as it facilitated the LMP1-induced
interaction of TAK1 with IKK2 (Supplementary Fig. 2b). The
data support a mechanism of IKK2 activation, in which TAK1
protein fosters signaling complex formation leading to NEMO
ubiquitination and the subsequent activation of IKK2 through
IKK2 autophosphorylation.
LMP1 activates TPL2 through IKK2. It was important to
identify the mediator of JNK activation downstream of IKK2.
TPL2 was a candidate, because it can be activated via IKK2 and its
overexpression induces JNK, although a role of IKK2 upstream of
TPL2 in JNK signaling has never been shown37,51,52. IKK2
directly phosphorylates TPL2 at serine 400 upon LPS stimula-
tion52. Also the expression of wildtype LMP1 or NGFR-LMP1
crosslinking induced serine 400 phosphorylation of TPL2 in
HEK293 cells (Fig. 4a, b, respectively). Activated TPL2 is unstable
and degrades37. Accodingly, degradation of endogenous
TPL2 started 1 h after NGFR-LMP1 crosslinking (Fig. 4c). An
important step in TPL2 activation by IKK2 is the release of TPL2
from p10537,52. To test if LMP1 acts through a similar molecular
mechanism on TPL2, wtHEK293:NGFR-LMP1wt cells were co-
transfected with Myc-tagged TPL2 and Flag-p105. The expression
levels of ectopic TPL2 did not alter following NGFR-LMP1
activation, however, this may be due to TPL2 overexpression.
Nevertheless, the amount of TPL2 complexed with p105
decreased from 60min after crosslinking (Fig. 4d). Altogether this
shows that LMP1 induces TPL2 phosphorylation, its release from
p105 and subsequent TPL2 degradation.
To confirm whether IKK2 functions upstream of TPL2 in the
LMP1 pathway, we tested if disruption of IKK2 affected TPL2
activation by LMP1. The downmodulation of IKK2 expression by
siRNA and its inhibition by ACHP blocked TPL2 degradation
induced by NGFR-LMP1 in MEFs (Fig. 4e, f, respectively). Also
the knockout of IKK2 prevented TPL2 degradation by NGFR-
LMP1, supporting the function of IKK2 as mediator of TPL2
activation in LMP1 signaling (Fig. 4g).
TPL2 is a component of the LMP1-induced JNK pathway.
TPL2 was targeted by siRNA in MEFs to assess if TPL2 is
involved in JNK activation by LMP1. Indeed, the knockdown of
TPL2 impaired JNK activation by NGFR-LMP1, demonstrating
an important function of TPL2 in this pathway (Fig. 5a). Treat-
ment with the ATP-competitive TPL2 inhibitor TC-S7006
reproduced the effects obtained with TPL2 siRNA (Fig. 5b).
Conversely, the downmodulation of TPL2 had no effect on
LMP1-induced IκBα degradation, which argues against an
essential role of this kinase in canonical NF-κB activation directly
downstream of IKK2 (Fig. 5a, b). CRISPR/Cas9 technology was
applied to target TPL2 in MEFs expressing NGFR-LMP1. The
knockout of TPL2 also caused diminished JNK activation by
LMP1, whereas IκBα degradation was not significantly affected
(Fig. 5c). Next, the TPL2 gene was targeted in HEK293 cells.
Three different TPL2-deficient HEK293 clones were transfected
with LMP1 wildtype or the AAA/Y384G mutant together with
HA-JNK1, and JNK1 activity assays were performed. JNK acti-
vation by LMP1 was substantially reduced in all three TPL2crKO
clones, supporting the results previously obtained in MEFs
(Supplementary Fig. 3a). Re-expression of TPL2 rescued JNK
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activation by LMP1 in HEK293 cells (Supplementary Fig. 3a).
Taken together, LMP1 engages TPL2 downstream of IKK2 to
activate the JNK pathway.
TPL2 is dispensable for IκBα/p65 NF-κB signaling by LMP1.
Neither TPL2 deficiency nor its pharmacological inhibition
were sufficient to block IκBα degradation induced by NGFR-
LMP1 (Fig. 5a–c). A role of TPL2 in NF-κB signaling by
CTAR2 has previously been suggested, albeit via conflicting
mechanisms26,45. Therefore, we analysed the effects of TPL2
deficiency on the canonical NF-κB pathway in more detail. The
knockout of TPL2 did not affect NGFR-LMP1-induced trans-
location of p65 NF-κB into the nucleus in MEFs (Supplemen-
tary Fig. 3b). Also serine 536 phosphorylation of nuclear p65
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NF-κB remained at wildtype levels in the TPL2 knockout cells
(Supplementary Fig. 3b). These results were further corrobo-
rated by the RNAi-mediated knockdown of TPL2 in MEFs,
which showed no effect on p65 NF-κB translocation induced by
LMP1 (Supplementary Fig. 3c). Full-length wildtype LMP1
induced the nuclear shift of p50 and p65 NF-κB in HEK293
cells, which was still the case in TPL2 knockout cells (Fig. 5d).
As expected, also the CTAR1-mediated shift of noncanonical
p52 and RelB remained detectable in the absence of TPL2
(Fig. 5d). Thus, TPL2 does not significantly contribute to the
activation of the canonical NF-κB pathway by LMP1 at the level
or upstream of NF-κB translocation.
Fig. 3 The role of TAK1 in JNK and NF-κB signaling by LMP1. a Pharmacological TAK1 inhibition blocks JNK, but not canonical NF-κB activation by LMP1.
NGFR-LMP1 was induced by antibody crosslinking in the presence of DMSO or 500 nM of the TAK1 inhibitor (5Z)−7-oxozeaenol (TAK1-IH). b LMP1-
induced IKK2 activity depends on the presence of TAK1 protein, but TAK1 kinase activity is dispensable. TAK1-deficient HEK293 cells (clone 3) or
corresponding wildtype cells were transfected with Flag-IKK2 together with HA-LMP1, the inactive mutant HA-LMP1(AAA/Y384G), or empty vector.
Where indicated, the cells were treated with 500 nM TAK1-IH for 5 h prior to cell lysis. Flag-IKK2 kinase assays were performed. IKK2 activity was
measured as radioactive GST-IκBα phosphorylation (topmost panel). Phosphorylation of immunoprecipitated Flag-IKK2 at serines 177/181 was detected on
immunoblots. c JNK activation by LMP1 requires both TAK1 protein and its kinase activity. Experiments were essentially performed as described under
c, except that HA-JNK1 was transfected and assayed using GST-c-Jun as substrate. For kinase assay quantification and statistics see Supplementary
Table 4. d IKK2 activation involves IKK2 autophosphorylation. HEK293 cells were transfected as indicated and treated with DMSO, IKK inhibitor ACHP or
TAK1-IH. Phosphorylation of imunoprecipitated Flag-IKK2 at serines 177/181 was detected. e LMP1 depends on TAK1 protein, but not its kinase activity, to
induce K63-ubiquitination of NEMO. HEK293 and TAK1crKOHEK293 cells were transfected with HA-Ubiquitin K63 and Flag-NEMO together with LMP1
wildtype or empty vector (w/o). After 24 h, cells were treated with 500 nM TAK1-IH where indicated. Flag-NEMO was immunoprecipitated (IP) using the
Flag (6F7) antibody. K63-linked ubiquitination of NEMO was detected by the HA (3F10) antibody. f TAK1 mediates IKK2 interaction with the LMP1
complex. HEK293 wildtype and TAK1crKO cells were transfected with Flag-IKK2 together with HA-LMP1 wildtype or AAA/Δ371–386 lacking CTAR2. Flag-
IKK2 was precipitated via the Flag (6F7) antibody and interacting LMP1 was detected by the HA (3F10) antibody. CRISPR/Cas9 knockouts were verified by
immunoblotting (This Figure) and by sequencing (see Supplementary Table 2). a–f The data are representative of at least two independent experiments.
a–b, d–f For immunoblot quantification and statistics see Supplementary Table 3.
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IKK2-TPL2 signal JNK activation by LMP1 in human B cells.
Human B cells are the main target cells of EBV. It was therefore
important to explore if this novel mechanism of JNK activation
by LMP1 via the IKK2-TPL2 axis is also operative in B cells.
Moreover, it was of interest to investigate if the LMP1 pathway to
JNK differs from CD40 signaling. To this end, human BL41
Burkitt’s lymphoma B cells expressing NGFR-LMP1 were either
crosslinked with antibodies to induce LMP1 activity or stimulated
with CD40 ligand in the presence or absence of inhibitors
(Fig. 6a–d and Supplementary Fig. 4). LMP1 executes a similar
molecular program to activate the JNK pathway in B cells as
identified above in other cell types. LMP1 relied on IKK2 and
TPL2 to activate JNK in BL41 cells (Fig. 6a, c, respectively). In
contrast to LMP1, CD40 signaling to JNK was independent of
IKK2 and TPL2 (Fig. 6b, d, respectively). The latter observation is
in line with previously published data excluding a role for TPL2
in JNK signaling by CD4040. The same authors showed that
CD40 activates the ERK pathway via TPL2 in primary murine B
cells40. Extending this, we observed that ERK activation by both
CD40 and LMP1 involves IKK2 and TPL2 in BL41 cells
(Fig. 6a–d). Finally, we addressed the role of TAK1 in CD40 and
LMP1 signaling. TAK1 kinase activity was required for JNK, but
not canonical NF-κB, activation by LMP1 in B cells, reflecting our
previous observations in non-B cells (Supplementary Fig. 4a). In
contrast, CD40 was dependent on the enzymatic activity of TAK1
to induce both NF-κB and JNK (Supplementary Fig. 4b). In
summary, the mechanism of JNK activation by LMP1 is similar
between B cells and non-B cells. Moreover, LMP1 and
CD40 signaling differ with respect to the molecular functions of
TAK1, IKK2, and TPL2.
To confirm the existence of the LMP1-induced IKK2-TPL2-
JNK pathway in EBV-transformed B cells, the natural context of
LMP1 function as an oncogene, we freshly infected primary
human B cells with recombinant EBV, in which the LMP1 gene
had been replaced by the NGFR-LMP1 chimera53. The resulting
LCL.NGFR-LMP1.6 lymphoblastoid cells fully depend on
LMP1 signals to proliferate (Fig. 6e). NGFR-LMP1 caused a
robust upregulation of the JNK and canonical NF-κB pathways
about 30 min after antibody crosslinking (Fig. 6f). As in non B
cells and BL41 cells, LMP1 signaling to JNK was fully dependent
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on IKK2 in these LCLs (Fig. 6f). Also IκB degradation induced by
NGFR-LMP1 was blocked by ACHP. TPL2 inhibition caused a
marked decrease in JNK activation, whereas induction of
canonical NF-κB was not affected. IKK2 and TPL2 are, thus,
mediators of JNK activation by LMP1 in EBV-transformed B
cells, which depend on LMP1 signals.
LCL survival is mediated by the IKK2-TPL2 pathway. As the
next step we evaluated the significance of the LMP1-induced
IKK2-TPL2 pathway in cell transformation by EBV. LMP1 drives
cell proliferation of LCLs and simultaneously protects cells from
apoptosis by induction of NF-κB and JNK1. Inhibition of the
canonical NF-κB pathway by expression of a dominant-negative
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IκBα caused cell death in LCLs20,54. Consistent with these data,
ACHP treatment strongly interfered with proliferation of LCLs
and LCL.NGFR-LMP1.6 cells (Supplementary Fig. 5a, b,
respectively).
However, as demonstrated above, IKK2 inhibition does not
discriminate between NF-κB and JNK downstream signaling. To
be more specific for the IKK2-TPL2 axis, we tested the effects of
TPL2 inhibition on LCLs. Steady-state phosphorylation of the
direct JNK target c-Jun, indicating cellular JNK activity levels, was
significantly reduced already 3 h after incubation of LCL721 cells
with TPL2 inhibitor (Fig. 7a). This result further confirmed that
the JNK pathway is dependent on TPL2 in LCLs. Of note, JNK
activity in LCLs is mediated by LMP15,15 (see Fig. 6f). In contrast,
IκBα levels remained unaffected by TPL2 inhibition, whereas
ACHP blocked canonical NF-κB and JNK in LCL721 cells
(Fig. 7a). Increased apoptosis was not detected at 3–6 h after
incubation with TPL2-IH, excluding cell death as an explanation
for the observed effects on the JNK pathway. TPL2 inhibition
efficiently retarded proliferation of the two lymphoblastoid cell
lines LCL721 and LCL 1C3 as well as of LCL.NGFR-LMP1.6 cells
(Fig. 7b and Supplementary Fig. 5b, respectively). TPL2-IH
elicited a strong apoptotic response in LCL721 and LCL 1C3 cells
after 24 and 48 h of TPL2 inhibition, demonstrating that TPL2 is
required for LCL survival (Fig. 7c). This effect was specific for
EBV/LMP1-transformed cells, because EBV-negative BL41 cells
remained unaffected by TPL2-IH treatment (Fig. 7d). In
accordance with the pro-survival function of TPL2 in lympho-
blastoid cells, TPL2-IH caused an upregulation of caspase 3
activity in both LCLs, which was comparable to the effects elicited
by the apoptosis inducer staurosporin (Fig. 7e).
LMP1-positive PTLD and carcinoma depend on IKK2-TPL2-
JNK. PTLD induced by EBV constitutes a severe complication in
transplant recipients. To test if the LMP1-IKK2-TPL2-JNK
pathway is also effective in PTLD, primary tumor cells were
established in culture from tumor biopsies of two PTLD patients,
resulting in PTLD099 and PTLD880 cells. LCL877 was generated
by parallel in vitro infection of primary B-cells of patient 880 with
B95.8 EBV and served as LCL control for PTLD880. The EBV-
encoded LMP1 genes expressed in PTLD099 and PTLD880 were
sequenced. The signaling domains of the two tumor-derived
LMP1 variants exhibit sequence alterations when compared to
B95.8 proto-type LMP1 and when compared to each other
(Supplementary Fig. 6). For instance, only LMP1 of PTLD880
carries an insertion of three 16-aa repeats. Moreover, both PTLD
variants of LMP1 carry point mutations at previously described
mutational hotspots (Supplementary Fig. 6 and references
therein). ACHP caused a marked reduction of c-Jun phosphor-
ylation levels in both PTLD samples as well as in the corre-
sponding LCL877, demonstrating a downregulation of JNK
activity by IKK2 inhibition in PTLD (Fig. 8a). ACHP also blocked
the canonical NF-κB pathway in these tumor cells as indicated by
IκBα stabilization (Fig. 8a). Notably, TPL2 inhibition interfered
with JNK activity in PTLD cells, too, whereas IκBα remained
unaffected (Fig. 8b). These results confirmed the relevance of the
IKK2-TPL2 pathway for JNK activation even in primary PTLD
tumor cells. Strikingly, this pathway is required for survival of
PTLD as pharmacological IKK2 and TPL2 inhibition very effi-
ciently blocked proliferation of PTLD cells and the corresponding
LCL (Fig. 8c, d, respectively).
LMP1 is also important for nasopharyngeal carcinoma
development in humans and it has oncogenic potential in rodent
fibroblasts. Expressed in the epidermis of mice, LMP1 induces
hyperplasia9. We therefore tested if TPL2 inhibition also affects
the survival of LMP1-positive murine carcinoma cells, which had
been established from mice expressing an LMP1 transgene
(LMP1tg) in the epidermis9,55. The LMP1tg-positive carcinoma
line 53.234a largely depends on LMP1 for efficient proliferation
and clonogenicity, whereas the LMP1tg-negative line 53.217 is
independent of LMP155. Indeed, TPL2 inhibition induced
apoptosis in the LMP1tg-dependent 53.234a carcinoma cells,
whereas 53.217 cells remained unaffected (Supplementary Fig. 7).
Taken together, the IKK2-TPL2 pathway is an important
mediator of JNK activation and survival of LMP1-transformed
cells, observed in a variety of cell and tumor types.
Discussion
Here we describe an important role of IKK2 and its interactor
NEMO in the activation of the JNK pathway, which is a new twist
in the molecular functions and biology of the canonical IKK
complex. The IKK2-dependent JNK pathway is a readout of the
EBV oncoprotein LMP1 in the context of cell transformation and
survival of tumor cells. LMP1 is among the most effective JNK
inducers, which requires this MAPK to exert its proliferative and
anti-apoptotic activity during B-cell growth transformation and
tumor development by EBV5,15,21. Several functions in tumor-
igenesis beyond NF-κB activation have been ascribed to IKK2,
including the regulation of p53 stability by direct phosphoryla-
tion56. Our findings extend the spectrum of IKK2 to a role in
oncogenic JNK signaling by engaging TPL2 as downstream
mediator. TPL2 has previously been implicated in cell transfor-
mation and cancer36. However, a critical role of TPL2 in JNK
signaling downstream of IKK2 has not been described. The IKK2-
TPL2-JNK axis is thus a new signaling module regulating cell
transformation.
Our results support a model of CTAR2 signaling to JNK and
NF-κB, which involves IKK2 as a key player for activation of both
pathways (Fig. 9). The CTAR2 signalosome includes TRAF6 as
critical component proximal to the receptor17,18. TRADD, TAK1,
TABs, TNIK, and the canonical IKK complex are further
recruited14,19,25,46,49. We show here that TAK1 mediates IKK
complex interaction with LMP1 and facilitates the ubiquitination
of NEMO independent of its kinase activity. Although the exact
mechanism whereby NEMO regulates IKK2 is still unknown,
NEMO ubiquitination is an important step preceding IKK2
activation28,34,56. IKK2 requires the phosphorylation of serine
residues 177 and 181 within its activation loop to be active28,34,56.
Direct phosphorylation of IKK2 by the IKK2 kinase TAK1 is the
most straightforward mechanism of IKK2 activation, as it has
been demonstrated for TNFα and IL-1 signaling32,33. The kinase
activity of TAK1, however, is not required for IKK2 induction by
LMP1. Also a potential role of the alternative IKK2 kinase
MEKK1 can be excluded, because LMP1 activates IKK2 in
MEKK1 knockout cells19. How is IKK2 phosphorylation then
achieved in LMP1 signaling? The requirement of TAK1 for IKK2
activation is not universal56,57. A discussed alternative scenario of
IKK2 activation independent of an IKK2 kinase involves IKK2
binding to ubiquitinated NEMO. This interaction may then
lead to conformational changes in IKK2, which facilitate
the herein observed autophosphorylation of IKK2 after LMP1
activation28,34. Despite being dispensable for the IKK2-TPL2 axis,
TAK1 kinase activity is obligatory for JNK activation by LMP1.
TAK1 kinase must act towards JNK in a second pathway parallel
to IKK2. Both TPL2 and TAK1 activate MAPK kinases (MKKs)
that are known to regulate JNK activity51,58. Likely, TPL2 and
TAK1 converge at the level of MKK4 and 7, which induce JNK
synergistically59. In summary, our findings define novel functions
of TAK1, NEMO, IKK2, and TPL2 in JNK signaling. They further
resolve inconsistent conclusions in the literature regarding the
role of TAK1 in LMP1 activation of JNK and NF-κB, which
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resulted from different methods of interference with TAK1
function19,26,46,47.
Although TPL2 is mainly involved in ERK activation by pro-
inflammatory agonists, it can contribute to optimal JNK
induction by TNFR1 in MEFs41. However, TNFR1 activates JNK
independently of IKK2, whereas JNK signaling by LMP1 relies
on the canonical IKK complex. How can these differences in
downstream signaling between the two receptors be explained?
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Fig. 7 TPL2 activity is required for proliferation and survival of EBV-transformed human B cells. a IKK2 and TPL2 inhibition causes downregulation of
the JNK pathway in lymphoblastoid cell lines (LCLs). Quantitative immunoblot analysis of LCL721 cells kept in the presence of DMSO, 10 µM of ACHP (left
panels) or TPL2-IH (right panels) for 3 h. The indicated antibodies were used. Paired signals standardized to total protein levels of three biological
replicates are shown. Chemiluminescence values (y-axes) are relative and do not allow for direct comparison between graphs. b TPL2 inhibition retards
proliferation of LCLs. LCL721 and LCL 1C3 cells were incubated in the absence or presence of DMSO or 10 µM TC-S7006 (TPL2-IH). Proliferation was
determined as MTT conversion. Data are mean values ± SD of three biological replicates. c TPL2 inhibition causes apoptosis in LCLs. Cells were kept in the
presence of DMSO or 10 µM TPL2-IH for 24 or 48 h, stained with propidium iodide (PI) and Annexin V-Cy5, and analysed by flow cytometry. FACS plots of
one representative experiment after 24 h are shown. Percentages of AnV+/PI− cells indicating apoptotic cells are given in graphs as mean values ± SD of
three biological replicates. d Cell death after TPL2 inhibition is specific for EBV-transformed B-cells. LCL721 and EBV-negative BL41 B-cells were grown in
the presence or absence of TPL2-IH for 24 h and apoptosis rates were determined. Data are mean values ± SD of three biological replicates. e The activity
of caspase 3 is increased in LCLs after TPL2 inhibition. Caspase 3 activity was measured after incubation of cells with DMSO or 10 µM TPL2-IH for 24 h.
Staurosporin treatment for 4 h served as positive control and reference. Data represent the x-fold change ± SD of three biological replicates. a Statistical
analysis was performed with the ratio paired T-test (two-tailed). b–e Statistical analysis was performed with two-way ANOVA at alpha 0.05. a–e p-values:
*p≤ 0.05, **p≤ 0.01, ***p≤ 0.001, n.s. not significant.
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TNFR1 requires TRAF2 and RIP1 to activate TPL2 and JNK41.
In contrast, LMP1-CTAR2 signaling to JNK fully depends on
TRAF6, whereas TRAF2 is largely dispensable1. CD40, which
activates JNK independently of IKK2 in our experiments, also
relies on TRAF2 for JNK signaling60. It is conceivable that the
signaling complexes of LMP1, TNFR1 and CD40 determine
different ubiquitination processes via engagement of different
TRAF ubiquitin ligases in combination with specific scaffolding
proteins such as TRADD or TNIK. In line with this hypothesis,
LMP1 was shown to activate IKK2 independently of the NEMO
zinc finger, which binds polyubiquitin chains and is required for
IKK2 activation by TNFα and CD4035,61.
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Fig. 8 The IKK2-TPL2-JNK pathway mediates proliferation of LMP1-expressing PTLD tumor cells. a IKK inhibition blocks the JNK and canonical NF-κB
pathways in PTLD. PTLD099 and PTLD880 cells isolated from two different PTLD tumor biopsies and LCL877 corresponding to PTLD880 were incubated with
DMSO or 10 µM of ACHP for 3 h. Chemiluminescence signals of immunoblots using the indicated antibodies were quantified directly. Paired signals
standardized to total protein levels of three biological replicates are shown. Chemiluminescence values (y-axes) are relative and do not allow for direct
comparison between graphs. b TPL2 mediates JNK, but not canonical NF-κB, activity in PTLD cells. The experiment was performed as described in a, except that
10 µM of TPL2 inhibitor TC-S7006 was used. Paired signals standardized to total protein levels of three (PTLD099, LCL877) or four (PTLD880) biological
replicates are shown. c ACHP blocks proliferation of PTLD tumor cells. Cells were incubated with or without DMSO, or in the presence of 10 µM of ACHP. At
the indicated times, MTT assays were performed. d TPL2 is required for PTLD proliferation. MTT assays in the presence of 10 µM of TPL2-IH. c, d The data are
mean values ± SD of three biological replicates. a, b Statistical analysis was performed with the ratio paired T-test (two-tailed). c, d Statistical analysis was
performed with two-way ANOVA at alpha 0.05. a–d p-values: *p≤0.05, **p≤0.01, ***p≤0.001, ****p≤0.0001, n.s. not significant.
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Previous reports suggested a role of TPL2 in NF-κB activation by
LMP1. The overexpression of dominant-negative TPL2(K167M)
showed negative effects on IκBα phosphorylation and p105 degra-
dation induced by LMP145. In another study the knockdown of
TPL2 reduced transcriptional NF-κB activity, but had no effect on
IκBα26. We showed here that LMP1-induced IκBα degradation and
nuclear translocation of NF-κB remain functional even in the
complete absence of TPL2. Possibly, overexpression of TPL2
(K167M) caused non-physiological effects on IκBα in the first study,
for instance by the TPL2 mutant competing with endogenous sig-
naling mediators for TRAF binding62. TPL2 might still be able to
crosstalk to the LMP1-induced NF-κB pathway by regulating the
transcriptional activity of NF-κB factors via secondary modifica-
tions or by regulating chromatin.
The LMP1-induced canonical NF-κB pathway is essential for
survival of lymphoblastoid cell lines20. Accordingly, pharmaco-
logical inhibition of IKK activity caused cell death of LCLs. Our
results now demonstrate that IKK inhibition combines deleter-
ious effects upon NF-κB signaling with the blockade of the JNK
pathway, which is also important for LCL proliferation21. IKK2
could be a potential target for the treatment of EBV-induced
malignancies. However, the NF-κB pathway is not only a weak
point of EBV-transformed tumor cells and many lymphomas, it is
also an important system in immune homeostasis29. Systemic
IKK inhibition might therefore cause many unwanted side effects.
Here we show that TPL2 inhibition interferes with survival of
LCLs, PTLD tumor cells and LMP1-dependent carcinoma cells.
TPL2 has previously been identified as target for anti-
inflammatory drugs, because it is selectively activated by
inflammatory stimuli63. Moreover, TPL2-deficient mice are
viable, develop normally and have life spans comparable to
wildtype littermates when kept under germ-free conditions39.
Drugs targeting TPL2 should therefore have fewer systemic side
effects than IKK inhibitors. On the basis of our results that TPL2
mediates oncogenic JNK signaling by LMP1 and cell survival of
EBV-transformed cells, TPL2 should be considered as an attrac-
tive target for new drugs or the repurposing of existing inhibitors
against EBV-induced malignancies such as PTLD in the future.
Methods
Cell lines and cell culture. HEK293 cells were obtained from the German Col-
lection of Microorganisms and Cell Cultures (DSMZ). IKK2−/− MEFs (provided
by M. Schmidt-Supprian) were established from IKK2 knockout mice64. The
lymphoblastoid cell line LCL 1C3 (provided by J. Mautner) was generated by
infection of primary human B cells with B95.8 EBV. BL41:NGFR-LMP1wt cells
(provided by J. Mautner), EBV-negative BL41 Burkitt lymphoma cells and LCL721
have been described and were taken from own laboratory stocks65–67. The LMP1
transgene (LMP1 tg)-positive carcinoma cell line 53.234a and corresponding
LMP1-negative 53.217 carcinoma cells were established from LMP1 tg mice or
LMP1-negative siblings, respectively and have been described55. HEK293:NGFR-
LMP1 cells were generated by PolyFect (Qiagen) transfection of HEK293 cells with
pSV-NGFR-LMP1 in combination with a hygromycin-resistance vector and sub-
sequent hygromycin selection. All mouse embryonic fibroblasts, derivatives thereof,
and murine carcinoma cells were cultured at 37 °C and 5% CO2 in Dulbecco's
modified eagle medium (DMEM) supplemented with 10% fetal calf serum (FCS)
and penicillin/streptomycin. HEK293 cells, HEK293 derivatives, and B cells were
kept in RPMI-1640 medium plus 10% FCS and penicillin/streptomycin. BL41:
NGFR-LMP1wt cells were grown in the presence of 1 µg/ml puromycin and
HEK293:NGFR-LMP1 cells in the presence of 100 µg/ml hygromycin. Cells were
stimulated with the indicated concentrations of recombinant human TNFα
(Applichem), murine interleukin-1 α (Tebu-Bio) or human recombinant soluble
CD40 ligand (Source BioScience). The inhibitors TC-S7006 (TPL2-IH, Biotechne),
(5Z)−7-oxozeaenol (TAK1-IH, Millipore), and ACHP (IKK Inhibitor VIII, Milli-
pore) were dissolved in DMSO and used as indicated.
Establishment of PTLD cells and LCLs. PTLD099 and PTLD880 cells were
established from anonymised tumor biopsies of two adult patients with cytopatho-
logically confirmed EBV-positive PTLD after allogeneic hematopoietic stem cell
transplantation. Tissue was disintegrated with scalpels in PBS and passed through a
100 μm Nylon cell strainer. Cells were washed and cultured in RPMI medium sup-
plemented with 10% FCS and penicillin/streptomycin in the presence of 1 μg/ml of
cyclosporine A (96-well plate, 5 × 105 cells per well in a volume of 200 µl). Half of the
culture supernatant was replaced every 5–7 days by fresh medium (containing
cyclosporine A for the first 4 weeks). When global cell proliferation was observed,
cultures were gradually expanded until stable cell proliferation in a volume of 10ml
was achieved. At this point (day 90 for PTLD099, day 62 for PTLD880), cells were
cryoconserved or further used in experiments. The LMP1 genes of PTLD099 and
PTLD880 were amplified by PCR and the signaling domains were sequenced. Primer
sequences are given in Supplementary Table 1. Lymphoblastoid cell line LCL877 was
derived from primary cells of the same PTLD biopsy that gave rise to PTLD880, but
was infected with EBV laboratory strain B95.8. Cells obtained as described above were
plated in medium with cyclosporine A containing 10 μl/well of filtered (0.7 μm)
supernatant from EBV-producing cell line B95.8. Cells were further cultivated and
expanded as described above for PTLD cell lines.
LCL.NGFR-LMP1.6 cells were established by infection and conditional
transformation of peripheral blood B cells of an adult EBV-negative donor with
recombinant maxi-EBV 2264.19, carrying NGFR-LMP1 instead of wildtype
LMP153. Initial outgrowth of infected B cells was supported by plating PBMCs on
top of an adherent layer of irradiated LL8 mouse fibroblasts expressing human
CD40L68. At day 14, the cells were removed from the feeder layer and since then
continuously cultivated in the presence of crosslinking antibodies (see NGFR-
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LMP1 crosslinking) to maintain LMP1 signals and proliferation. After 8 weeks, the
culture expanded to approximately 106 cells and was used for experiments.
Ethics. We complied with all relevant ethical regulations for work with human
participants. Anonymised human PTLD biopsies and blood from a healthy human
donor were obtained with informed consent as approved by the Institutional
Review Board (Ethics Commission of the Faculty of Medicine of the Ludwig-
Maximilians-University Munich, project no. 071–06–075–06).
Plasmids. The plasmids pCMV-HA-LMP1 wildtype, pCMV-HA-LMP1(AAA/
Δ371–386) harboring a P204xQxT to AxAxA mutation within CTAR1 and lacking
the 16 C-terminal amino acids of CTAR2, pCMV-HA-LMP1(AAA/Y384G), pSV-
LMP1, pSV-LMP1(Y384G), pcDNA3-Flag-IKK2, and pRK5-HA-JNK1 have been
described16,49. The vector pSV-NGFR-LMP1 encoding a fusion protein of aa 1–279
of human low affinity p75 NGF-receptor and aa 196–386 of LMP1 has been
described17,48. pCMV5-TPL2wt.MT (provided by C. Patriotis) and pcDNA3-Flag-
p105 (provided by D. Krappmann) have been described69,70. The vector pEF4C-
3xFlag-IKKγwt (NEMO) was a kind gift of D. Krappmann. pRK5-HA-Ubiquitin
K63 (all lysines mutated to arginines except of K63) was obtained from Addgene
and has been described71.
Retroviral transduction. NGFR-LMP1 wildtype and NGFR-LMP1(Y384G) were
subcloned from pSV-NGFR-LMP1 into the retroviral vector pSF91-IRES-GFP-
WPRE (provided by C. Baum)72. For virus production, phoenix-gp cells were
transfected with pSF91-NGFR-LMP1-IRES-GFP-WPRE, gag-pol vector and
pEcoEnv expressing ecotropic Env protein as described21. MEFs were infected and
sorted for low and comparable GFP expression levels using a MoFlo cell sorter
(Beckman Coulter). NGFR-LMP1 expression at the cell surface of the resulting
bulk cultures was analysed by staining with Alexa647-conjugated NGFR antibody
(#557714, BD Pharmingen) and subsequent flow cytometry using a FACS Calibur
flow cytometer (Becton Dickinson). Data processing was performed with FlowJo
software.
CRISPR/Cas9 gene targeting. U6gRNA-Cas9-2A-GFP gene targeting vectors
were obtained from Sigma-Aldrich and expressed Cas9, GFP and the following
gRNAs: murine MM0000145296 (IKK1), MM0000125118 (NEMO), and
MM0000226028 (TPL2), human HS0000099337 (NEMO), HS0000206639 (TPL2),
and HS0000272768 (TAK1). Cells were co-transfected with targeting vector and a
puromycin selection plasmid using PolyFect (Qiagen). Twenty-four hours after
transfection, cells were seeded in different dilutions into 15 cm cell culture plates in
the presence of 1.5 µg/ml puromycin. After 30 h, selection pressure was removed by
washing with PBS and the cells were cultured for 2–3 weeks in standard cell culture
medium. GFP-negative single clones, which had lost the targeting vector, were
propagated and tested for successful gene targeting by immunoblotting and
sequencing. For the latter, genomic DNA of the targeted region was amplified by
PCR and sequenced (Results, see Supplementary Table 2). Primer sequences are
provided in Supplementary Table 1. Gene loci targeted by CRISPR/Cas9 in cell
culture were named crKO to distinguish them from classical gene knockouts by
homologous recombination.
RNA interference. Mouse embryonic fibroblasts were transfected twice within
24 h, each time with 100 nM of ON TARGETplus SMART-pool (pool of 4 siRNAs)
TPL2 siRNA L-040683-00, IKK1 siRNA L-041014-00, IKK2 siRNA L-040630-00 as
indicated, or non-targeting control siRNA using the Dharmafect 1 transfection
reagent (all: Dharmacon) according to the manufacturer´s protocol. Cells were
stimulated and further analysed as indicated 1 day after the last transfection
with siRNA.
NGFR-LMP1 crosslinking and inhibitors. For crosslinking experiments, 5 × 105
cells were seeded in 6 cm dishes or 1.5 × 106 cells in 10 cm dishes and starved
overnight in FCS-free medium. The cells were incubated for 45 min at 37 °C with
1 µg/ml of anti-NGFR HB8737 primary antibody (ATCC). NGFR-LMP1 activity
was induced by crosslinking with 10 µg/ml of anti-mouse IgG/IgM secondary
antibody (#115-005-068, Dianova) for the indicated times. BL41:NGFR-LMP1 and
LCL.NGFR-LMP1.6 cells were crosslinked in suspension. TPL2 and TAK1 inhi-
bitors were added 3–5 h and the IKK inhibitor 30 min prior to antibody incubation
and were present throughout crosslinking.
Immunoblotting and quantification, immunoprecipitation. For immunoblotting
and immunoprecipitation cells were lysed on ice in NP-40 lysis buffer (50mMHEPES
pH 7.5, 150mM NaCl, 5mM EDTA, 0.1% NP-40) supplemented with phosphatase
inhibitors (0.5mM sodium orthovanadate, 0.5mM NaF, 0.5mM sodium molybdate,
0.5mM sodium pyrophosphate, 50 mM β-glycerophosphate) and complete proteinase
inhibitor (Roche). Lysates were cleared by centrifugation, separated by SDS-PAGE on
12.5% SDS-PAA gels, and blotted to nitrocellulose membrane (Bio-Rad). Immuno-
blots were visualized using a secondary antibody coupled to horseradish peroxidase
and ECL reagent. For quantification of ECL signals captured on X-ray films, signals
were analysed by densitometry using the ImageJ software. Results are shown in
Supplementary Table 3. ECL chemiluminescence signals of Figs. 7a, 8a, b were
detected directly by the Vilber Fusion FX6 Edge imager and analysed by the Vilber
Bio-1D software. Signals were standardized to total protein levels. Statistical analysis
was performed using the GraphPad Prism 6 software (see Statistical analysis). For co-
immunoprecipitations, the cells were transfected in 15 cm dishes with the indicated
plasmids using PolyFect transfection. Twenty-four hours of post transfection, cells
were lysed in NP-40 lysis buffer and proteins of interest were immunoprecipitated by
incubation for 3 h with the indicated antibodies covalently coupled to protein
G-sepharose beads. The following primary antibodies were used: Cot (TPL2)
M20 (sc-720, used at 1:500 dilution), IκBα C21 (sc-371, 1:1000), IKKα (IKK1) M280
(sc-7182, 1:500), IKKα/β (IKK1/2) H470 (sc-7607, 1:500), IKKγ (NEMO) FL419
(sc-8330, 1:500), JNK1/3 C17 (sc-474, 1:500), c-Jun H79 (sc-1694, 1:500), NF-κB p50
C19 (sc-1190, 1:500), RelB C19 (sc-226, 1:500), Sam68 C20 (sc-333, 1:1000), TAK1
M579 (sc-7162, 1:500), TRAF3 C20 (sc-949, 1:500), Tubulin B-5-1-2 (sc-23948,
1:5000) (all: Santa Cruz Biotech.), ERK1/2 p44/42 (#9102, 1:1000), P-ERK1/2 Thr202/
Tyr204 (#9101, 1:1000), P-JNK Thr183/Tyr185 (#9251, 1:1000), P-JNK Thr183/
Tyr185 (#4668, 1:1000), P-c-Jun Ser73 (#3270, 1:1000), P-IKKα/β (IKK1/2) Ser177/
181 of IKK2 (#2697, 1:1000), NF-κB p65 (#4764, 1:1000), NF-κB p100/p52 (#4882,
1:1000), P-TPL2 Ser400 (#4491, 1:500), P-p65 Ser536 (#3033, 1:1000), (all: Cell Sig-
naling Technology), P-JNK1+ 2+ 3 Thr183+Thr183+Tyr221 (ab124956,
Abcam, 1:1000), NF-κB p105 (PA5-17150, 1:1000) (Thermo Scientific), HA 3F10
(11867423001, 1:1000), Flag 6F7 (SAB4200071, 1:1000), Myc 9E10 (SAB4700447,
1:1000) (all: Sigma-Aldrich), and LMP1 1G6-325,55,73 (provided by E. Kremmer,
hybridoma supernatant used at 1:5 dilution).
Immunocomplex kinase assays and quantification. HEK293 cells were trans-
fected in six-well plates with 1 µg each of the indicated constructs and 1 µg of
pRK5-HA-JNK1 or 0.25 µg of pcDNA3-Flag-IKK2 using PolyFect transfection. For
TPL2 rescues, 0.1 µg of TPL2-myc expression vector was co-transfected in Sup-
plementary Fig. 3a. Twenty-four hours after transfection, cells were lysed in NP-40
lysis buffer and HA-JNK1 or Flag-IKK2 were immunoprecipitated via their epitope
tags. Beads were washed twice with NP-40 lysis buffer and twice with kinase
reaction buffer (20 mM Tris-HCL pH 7.4, 20 mM NaCl, 10 mMMgCl2, 2 μM DTT,
2 μM ATP). In vitro kinase reactions were performed in the presence of 10 μCi
γ32P-ATP and 1 µg of recombinant GST-c-Jun or GST-IκBα, respectively, for 25
min at 27 °C74. Samples were subjected to SDS-PAGE and autoradiography.
Radioactive signals were quantified using the Typhoon FLA-7000 phosphoimager
(GE Healthcare) and normalized to the amounts of immunoprecipitated kinase.
Quantitative kinase assay results are shown in Supplementary Table 4.
Nuclear shift assay. HEK293 cells and MEFs were treated in 10 cm dishes as
indicated before cell lysis. Cells were washed in PBS at 4 °C and lysed in 100 µl of
swelling buffer (10 mM HEPES pH 7.9, 10 mM KCl, 0.1 mM EDTA, 0.1 mM
EGTA, 1 mM DTT, 1 mM phenylmethylsulfonyl flouride) on ice for 15 min. After
adding of 0.65% NP-40, the samples were incubated for 5 min at 4 °C under gentle
rocking. After centrifugation for 10 min at 15,000 × g, the supernatants repre-
senting the cytosolic fraction were collected. Pellets were washed with swelling
buffer and lysed in 50 µl of nuclear extraction buffer (20 mM HEPES pH 7.9,
400 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1 mM DTT, and 1 mM phe-
nylmethylsulfonyl flouride). Insoluble debris was removed by centrifugation.
Tubulin (cytoplasmic fraction) and Sam68 (nuclear fraction) served as marker
proteins for purity of the preparation.
NEMO ubiquitination. HEK293 cells were transfected in 10 cm dishes with the
indicated expression vectors, pEF4C-3xFlag-IKKγwt (NEMO) and pRK5-HA-
ubiquitin K63. Cells were lysed 24 h post transfection in NP-40 lysis buffer sup-
plemented with 10 mM N-ethylmaleimide. Flag-NEMO was immunoprecipitated
via its Flag-tag and K63 linked ubiquitination was analysed by immunoblotting
with HA primary antibody recognizing HA-Ub K63 modification of Flag-NEMO.
Cell proliferation and apoptosis. Metabolic MTT (3-(4,5-dimethylthiazol-2-yl)
−2,5-diphenyltetrazolium bromide) conversion by viable cells was used to monitor
cell expansion as described5. At day 0, 10,000 cells were seeded per well of a 96-well
plate in triplicates and analysed after the indicated times. Apoptosis was assayed by
staining of the cells with propidium iodide (PI) and Cy5-labeled annexin V using
the Annexin V-Cy5 Apoptosis Detection Kit (K103, Biovision) as described in the
manufacturer’s protocol. Flow cytometric analysis of PI and annexin V-Cy5
staining was performed with the FACS CantoII flow cytometer (Becton Dickinson).
FACS data were analysed with FlowJo X.0.7 software. The gating strategy for
apoptosis assays is shown in Supplementary Fig. 8. All cells were included into the
analysis, whereas cell debris was excluded.
Caspase activity assay. Caspase 3 activity was monitored using the Caspase Col-
orimetric Substrate Set Kit (#K132, Biovision) according to the manufacturer’s pro-
tocol. Cells were treated as indicated with 10 µM TC-S7006 for 24 h before cell lysis.
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Caspase 3 substrate was added to the lysates and incubated for 2 h at 37 °C. Caspase 3
activity was measured as colorimetric substrate conversion at 405 nm wavelength.
Statistical analysis. Statistics was performed using Graphpad Prism 6 software. T-
test (two-tailed) was performed for unpaired samples (Supplementary Tables 3, 4).
Two-way ANOVA analysis was performed for grouped samples. Ratio paired T-
test (two-tailed) was applied for paired samples (Figs. 7a, 8a, b).
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availabilty
LMP1 sequencing data have been deposited in GenBank under the accession codes
MN244676 for PTLD099 and MN244677 for PTLD880. Original uncropped scans of
blots and other important original data are supplied in the Source Data file.
Received: 12 June 2018; Accepted: 10 December 2019;
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